Evidence map›Paper›PMID 34737323›Full record

ArticleScientific reports2021

High sensitivity-low cost detection of SARS-CoV-2 by two steps end point RT-PCR with agarose gel electrophoresis visualization.

Solange Figueroa, Byron Freire-Paspuel, Patricio Vega-Mariño, Alberto Velez, Marilyn Cruz, Washington B Cardenas, Miguel Angel Garcia-Bereguiain

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Solange Figueroa *One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
Byron Freire-Paspuel *One Health Research Group, Universidad de Las Americas, Quito, Ecuador.
Patricio Vega-MariñoAgencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos, Puerto Ayora, Ecuador.
Alberto VelezAgencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos, Puerto Ayora, Ecuador.
Marilyn CruzAgencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos, Puerto Ayora, Ecuador.
Washington B CardenasLaboratorio para Investigaciones Biomédicas, Escuela Superior Politécnica del Litoral, Guayaquil, Ecuador.
Miguel Angel Garcia-BereguiainOne Health Research Group, Universidad de Las Americas, Quito, Ecuador. magbereguiain@gmail.com.
Charles Darwin Foundation · ECUniversidad de Las Américas · ECEscuela Superior Politecnica del Litoral · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than one year since Coronavirus disease 2019 (COVID-19) pandemic outbreak, the gold standard technique for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection is still the RT-qPCR. This is a limitation to increase testing capacities, particularly at developing countries, as expensive reagents and equipment are required. We developed a two steps end point RT-PCR reaction with SARS-CoV-2 Nucleocapsid (N) gene and Ribonuclease P (RNase P) specific primers where viral amplicons were verified by agarose gel electrophoresis. We carried out a clinical performance and analytical sensitivity evaluation for this two-steps end point RT-PCR method with 242 nasopharyngeal samples using the CDC RT-qPCR protocol as a gold standard technique. With a specificity of 95.8%, a sensitivity of 95.1%, and a limit of detection of 20 viral RNA copies/uL, this two steps end point RT-PCR assay is an affordable and reliable method for SARS-CoV-2 detection. This protocol would allow to extend COVID-19 diagnosis to basic molecular biology laboratories with a potential positive impact in surveillance programs at developing countries.

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19COVID-19 Nucleic Acid TestingCOVID-19 TestingDNA PrimersElectrophoresis, Agar GelHumansLaboratoriesNasopharynxRibonuclease PRNA, ViralSARS-CoV-2Sensitivity and SpecificityCoronavirus Nucleocapsid ProteinsDNA PrimersRibonuclease PRNA, Viral

Identifiers

PMID34737323
PMCPMC8568942
OpenAlexW3208526875

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.